Cambridgeshire -- (MARKET WIRE) -- February 15, 2007 --
For Immediate Release 15 February 2007
BioProgress plc
BioProgress to present at 19th Annual Roth Capital
Partners Growth Stock Conference
London, UK, 15 February 2007: BioProgress plc ('BioProgress' or the 'Company')
(AIM: BPRG; NASDAQ: BPRG), the speciality pharmaceutical and healthcare company,
announces that the Company will make a presentation at the 19th Annual Roth
Capital Partners Growth Stock Conference, being held from February 19 - 22 in
Laguna, California, USA.
For further information:
BioProgress Plc + 44 (0) 20 7098 9881
Richard Trevillion, CEO
Steve Martin, CDO
Buchanan Communications + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court
About BioProgress
BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the
company has over 80 patents granted or in application within 24 patent families
and has product development agreements and strategic alliances with several
global companies. As a vertically integrated business, BioProgress has
acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. The business continues to
develop innovative delivery mechanisms using its XGELTM polymer technology,
replacing the need to use animal-derived gelatine in pharmaceutical and
healthcare products. For further information please go to
www.bioprogress.com
Forward-Looking Information
The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934. To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies. These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances. Actual results may vary materially from the
expectations contained in the forward-looking statements. The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation. Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company"s filings with the
Securities and Exchange Commission. The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice. The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law. Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.
This information is provided by RNS
The company news service from the London Stock Exchange